How many clinical trials are studying Mirikizumab?

8 recruiting trials in our tracked data involve Mirikizumab.

What conditions is Mirikizumab being studied for?

In our tracked recruiting trials, Mirikizumab is being studied in trials for Ulcerative Colitis, Crohn's Disease, Obesity.

Mirikizumab: clinical trials recruiting now

Q: Is Mirikizumab FDA-approved?

Yes. According to the FDA drug label available through openFDA, Mirikizumab is an FDA-approved drug.

Recruiting trials

Conditions studied

US states with sites

Countries

FDA drug label

FDA-approved: Yes. Mirikizumab appears in the FDA drug-label database. Marketed as Omvoh.
Drug class: Interleukin-23 Antagonist (FDA established pharmacologic class)
Mechanism of action: Interleukin-23 Antagonists (as stated on the FDA label)

FDA-approved use

OMVOH is indicated for the treatment of: moderately to severely active ulcerative colitis in adults. moderately to severely active Crohn's disease in adults. OMVOH TM is an interleukin-23 antagonist indicated for the treatment of: moderately to severely active ulcerative colitis in adults ( 1 ) moderately to severely active Crohn's disease in adults ( 1 )

FDA label via openFDA

Phase breakdown

Phase 2 2 Phase 3 4 Phase 4 2

Conditions being studied

Condition	Trials
Ulcerative Colitis · Mirikizumab for Ulcerative Colitis	5
Crohn's Disease · Mirikizumab for Crohn's Disease	4
Obesity	2
Obesity or Overweight	2
Ulcerative Colitis Chronic	2
Crohn Disease	1
Inflammatory Bowel Diseases	1
Ulcerative Colitis (UC)	1

Recruiting trials involving Mirikizumab

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
NCT04844606 · Phase: Phase 3 · Ages: 2 Years to 19 Years · Sex: All (male and female) · 136 locations
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
NCT06598943 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 207 locations
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
NCT05509777 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · 81 locations
Efficacy of Top-down Therapy With Mirikizumab Versus Standard of Care With Azathioprine in Patients With Newly Diagnosed Moderate-to-severe Ulcerative Colitis
NCT07235904 · Phase: Phase 4 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
NCT07186101 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 147 locations
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
NCT06937086 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 374 locations
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
NCT06937099 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 183 locations
Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD
NCT06997965 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations

Common questions

Is Mirikizumab FDA-approved?

Yes, marketed as Omvoh.

How many recruiting trials involve Mirikizumab?

8 recruiting trials across 8 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.